PA
NGNE icon

Parallel Advisors’s Neurogene NGNE Stock Holding History

Parallel Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1K Sell
35
-61
-64% -$1.68K ﹤0.01% 3669
2026
Q1 		$1.94K Buy
+96
New +$1.86K ﹤0.01% 3386
2021
Q4 		– Sell
-3
Closed – – 3217
2021
Q3 		$0 Buy
+3
New +$459 ﹤0.01% 3204

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Parallel Advisors's NGNE Position: Q2 2026 in Review

Parallel Advisors reduced its Neurogene (NGNE) stake by 64% in Q2 2026, selling an estimated $1.68K and leaving 35 shares worth $1.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3669.

Parallel Advisors first reported a position in NGNE in Q3 2021 and has held it in 3 quarters since. The position peaked at $1.94K in Q1 2026. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Parallel Advisors held 35 shares of Neurogene worth $1.1K as of Q2 2026.
  • Parallel Advisors sold 61 Neurogene shares in Q2 2026, an estimated $1.68K.
  • Neurogene made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3669 holding.
  • Parallel Advisors first reported a position in Neurogene in Q3 2021 and has held it in 3 quarters since.
  • Parallel Advisors's Neurogene position peaked at $1.94K in Q1 2026.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.